| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | |
|---|---|---|---|---|---|---|
| 08:30 - 09:00 | Registration & Opening |
Shou-Tung Chen
|
||||
| 09:00 - 09:30 | Regulatory and Operational Challenges in Conducting Asian International Academic Trials for Expanding the Indications of Cancer Drugs |
Kenji Tamura
|
||||
| 09:30 - 10:00 | Are All Triple Negative Breast Cancers the Same? |
Jorge S. Reis-Filho
|
||||
| 10:00 - 10:30 | Current Status and Future Prospects of Immunotherapy in Breast Cancer Treatment: Past, Present, and Future |
Tan Jing Ying Tira
|
||||
| 10:30 - 10:50 | Coffee Break | |||||
| 10:50 - 11:20 | Precision Immunotherapy for TNBC: From Clinical Factors to Tumor Microenvironment |
Giampaolo Bianchini
|
||||
| 11:20 - 11:50 | Diagnostic and Therapeutic Considerations in Tumor Microenvironments |
Mark Pegram
|
||||
| 11:50 - 12:10 | Panel Discussion |
Giampaolo Bianchini
Mark Pegram
Jorge S. Reis-Filho
Tan Jing Ying Tira
|
||||
| 12:10 - 12:50 | Docetaxel, Aging Like a Fine Wine |
Chun-Yu Liu
|
||||
| 12:50 - 13:10 | Coffee Break | |||||
| 13:10 - 13:40 | The Sustainable Efficacy of CDK4/6 Inhibitor Therapy in HR+/Her2- Node+ High Risk Early Breast Cancer |
Nadia Harbeck
|
||||
| 13:40 - 14:10 | Adjuvant Treatment for Young Age ER+ Early Breast Cancer (EBC) |
Prudence Francis
|
||||
| 14:10 - 14:40 | Bridging Treatment Gaps for Stage II and III HR+/HER2- Early Breast Cancer with CDK4/6 Inhibitors | |||||
| 14:40 - 15:00 | Coffee Break | |||||
| 15:00 - 15:30 | Optimal Management of Hormone Receptor Positive Metastatic Breast Cancer |
Hope S. Rugo
|
||||
| 15:30 - 16:00 | Novel Strategies to Overcome Resistance to Endocrine Therapy in HR+ aBC: From Biological Perspectives to Clinical Advances |
Javier Cortés
|
||||
| 16:00 - 16:20 | Panel Discussion |
Javier Cortés
Prudence Francis
Hope S. Rugo
|
||||
| 16:20 - 16:50 | Unveiling the Myth of Trop-2 ADC Science and Prospects for Future Development |
Leif Ellisen
|
||||
| 16:50 - 17:20 | Riding the Wave of Innovation: The evolving landscape of ADCs in Breast Cancer Treatment |
Paolo Tarantino
|
||||
| 17:20 - 17:50 | Optimizing Survival: Individualized Adjuvant Strategies for Maximizing Neoadjuvant Benefits |
Sibylle Loibl
|
||||
| 17:50 - 18:10 | Panel Discussion |
Leif Ellisen
Sibylle Loibl
Paolo Tarantino
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | |
|---|---|---|---|---|---|---|
| 10:30 - 10:50 | Screening, Diagnosis and Surveillance Between East and West |
Eun Sook Ko
|
||||
| 10:50 - 11:10 | Difference in Surgical Considerations and Oncoplastic Surgery Between East and West |
Wen-Ling Kuo
|
||||
| 11:10 - 11:30 | Difference in Medical Considerations and Survivorship Between East and West |
Hyun Jo Youn
|
||||
| 11:30 - 12:00 | Panel Discussion:What Are the Unique Surgical Needs in Asian Population and How to Meet Them? |
Wen-Ling Kuo
Eun Sook Ko
Hyun Jo Youn
|
||||
| 13:00 - 13:05 | Young Doctors Forum/Debate Opening |
Hsu-Huan Chou
|
||||
| 13:05 - 13:30 | [YDF] How to ask translational questions? |
Shiuan Chen
|
Hsu-Huan Chou
|
|||
| 13:30 - 13:55 | [YDF] What Are the Opportunities for Young Doctors to Innovate Within the Medical System and Drive Positive Change? |
Jeong Eon Lee
|
Hsu-Huan Chou
|
|||
| 13:55 - 14:00 | [YDF] Q&A |
Hsu-Huan Chou
|
||||
| 14:00 - 14:40 | [YDD Topic 1] Should ALND Be Performed in ypN1micro Luminal Breast Cancer Patient with Initial cN1 After Neoadjuvant Chemotherapy? |
Wen-Ling Kuo
|
||||
| 14:40 - 15:20 | [YDD Topic 2] Should Adjuvant Pembrolizumab Be Considered in Early TNBC Patients Achieving pCR After Neoadjuvant Chemotherapy Combined with Immunotherapy? |
Chun-Yu Liu
|
||||
| 15:20 - 15:30 | [YDD] Q&A Closing |
Chi-Cheng Huang
|
| Time (UTC+8) | Topic | Speaker | Moderator | Abstract | Slides | |
|---|---|---|---|---|---|---|
| 08:20 - 08:50 | The Current Role of Combination Chemotherapy in Metastatic Breast Cancer Treatment |
Ta-Chung Chao
|
||||
| 08:50 - 09:20 | Axillary Surgery in Clinically Node Negative and Positive Disease: Current Indication | |||||
| 09:20 - 10:00 | Current Topics in Breast Cancer Radiation Oncology: Axillary Management, Multi-Centric Disease, and Second Breast-Conserving Therapy |
Philip Poortmans
|
||||
| 10:00 - 10:30 | What Can We Do to Avoid Axillary Lymph Node Dissection When There Is Metastatic Lymph Node on Sonogram? |
Jana de Boniface
|
||||
| 10:30 - 10:50 | Panel Discussion |
Jana de Boniface
Philip Poortmans
|
||||
| 10:50 - 11:10 | Coffee Break | |||||
| 11:10 - 11:40 | Breast Cancer Biology for Precision Medicine |
Christos Sotiriou
|
||||
| 11:40 - 12:10 | From Consistent 1L CDK4/6i Evidence-Based Survival Benefit to Real-World Clinical Practice in HR+HER2- mBC |
Shih-Yu Huang
|
||||
| 12:10 - 12:50 | Real World Evidence: Astragalus polysaccharides Injection and Breast Cancer Patients with Cancer-related Fatigue |
Ming-Shen Dai
|
||||
| 13:10 - 13:40 | Unmet Needs in Early-Stage HER2-Positive Breast Cancer: The Benefit of Extended Adjuvant Treatment |
Hsu-Huan Chou
|
||||
| 13:40 - 14:10 | Cancer Therapy-Associated Cardiomyopathy: Practice Considerations |
Wei-Ting Chang
|
||||
| 14:10 - 14:40 | Navigating the Intersection of Breast cancer and Bone Health: the Role of Denosumab in Preventing Skeletal-Related Events |
Li-Chun Kao
|
||||
| 14:40 - 15:00 | Coffee Break | |||||
| 15:00 - 15:30 | Potential Role of TIL Assessment in Clinical Practice |
Sherene Loi
|
||||
| 15:30 - 16:00 | What Should We Do on Monday Morning? |
Dwan-Ying Chang
Yuan-Ching Chang
Wei-Pang Chung
|
||||
| 16:00 - 16:20 | Award Ceremony & Closing |